LBT Innovations Pioneers AI in Microbiology Labs

LBT Innovations Limited (AU:LBT) has released an update.

LBT Innovations, hailing from Adelaide, has revolutionized microbiology labs with its Automated Plate Assessment System (APAS® Independence), an AI-driven technology for analyzing culture plates, which is notably the only FDA-approved AI for this purpose. The company is actively commercializing this technology through its subsidiary, Clever Culture Systems AG, targeting the pharmaceutical and clinical lab sectors, with Thermo Fisher Scientific as the exclusive distributor in the US and parts of Europe.

For further insights into AU:LBT stock, check out TipRanks’ Stock Analysis page.